Founded in 2009, SynDermix is a Swiss clinical-stage biotechnology company financed by private investors. Powered by three technology platforms and defined by synergism, our focus is on the development of frontier pipeline candidates that target disorders affecting the epithelial tissues of the human body, and which improve their well-being. SynDermix identifies and acquires the rights to promising early-stage pipeline candidates, which we develop until a robust demonstration of their innovation (IP) and clinical value. We outsource the execution of these activities to our global network of specialist partners, facilitating the time- and resource- efficient management of our pipeline cycle and promoting process excellence. We then enter into corporate partnerships for market access. We operate a lean structure, which leverages the complementary expertise of a seasoned executive team and a broad network of selected service providers and key opinion leaders. Our focus is on products of natural origin that address unmet healthcare needs and wellcare demands. This strategy enables us to benefit from accelerated timelines to market access, e.g. through Orphan Drug Designation, registration as a medical device or as a cosmetic product. Our portfolio is currently based on three proprietary technology platforms: lectins, nitric oxide and vibration therapies. These platforms provide a broad range of health and wellcare products with indications that include oral mucositis, gastrointestinal ulceration, wound-healing, chronic rhinosinusitis, migraine and skin-ageing. Our most advanced biopharmaceutical product is entering Phase II/III development for the treatment of oral mucositis, while our wellcare product against skin-ageing is expected to enter the market by end of 2018.